Evotec (ETR:EVT) Stock Crosses Above 50-Day Moving Average – Here’s What Happened

Evotec SE (ETR:EVT)’s stock price crossed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of €4.83 and traded as high as €5.23. Evotec shares last traded at €5.23, with a volume of 605,744 shares traded.

Evotec Trading Down 3.7%

The business’s fifty day simple moving average is €4.83 and its 200 day simple moving average is €5.40. The company has a current ratio of 1.68, a quick ratio of 2.97 and a debt-to-equity ratio of 55.38. The stock has a market cap of $934.22 million, a P/E ratio of -5.45, a price-to-earnings-growth ratio of 0.98 and a beta of 1.30.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic.